Facebook-square Linkedin Instagram Youtube

Outset Medical, Inc.

Johnson Fistel Begins Investigation into Outset Medical Following a 50% Drop in the Company’s Stock

Shareholder rights law firm Johnson Fistel, LLP is investigating whether Outset Medical, Inc. (NASDAQ: OM) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.

What if I purchased Outset Medical securities? If you purchased securities and suffered losses on your investment, join our investigation now:

If you suffered a loss on your investment and would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. The information provided will be held in strict confidence unless and until you authorize us to disclose it.
Name(Required)
Would you like to receive future case and securities updates from Johnson Fistel, LLP via email?(Required)
Would you like to receive information about Johnson Fistel, LLP's free portfolio monitoring service?(Required)
By checking the box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Johnson Fistel, LLP, and that submission to or receipt of information from the firm or one of its attorneys via this form, website, email, or telephone does not create an attorney-client relationship.(Required)

Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.

There is no cost or obligation to you.

What is Johnson Fistel investigating? On August 7, 2024, Outset Medical reported its second-quarter financial results, revealing a notable decrease in revenue and a downward adjustment in its full-year guidance. The company’s revenue for Q2 2024 fell to $27.4 million, a significant drop from $36.0 million in the same period the previous year. Product revenue also diminished, reaching only $19.2 million. Additionally, new console placements did not meet expectations, further impacting overall performance. As a result, Outset Medical revised its full-year 2024 revenue guidance to $110 million, a substantial reduction from the earlier projected range of $145 to $153 million. Following this news, Outset Medical stock was trading down 59% during early morning trading on August 8, 2024.

Please contact us if you would like more information on this lawsuit.
©2024 Johnson Fistel, LLP - All Rights Reserved.